What Is a Thyroid RFA System for Benign Nodules?
Thyroid nodules affect millions of patients, yet not every case calls for thyroid removal. For clinicians looking to preserve thyroid function while addressing symptomatic benign nodules, thyroid RFA systems represent a compelling minimally invasive alternative. This article explores how radiofrequency ablation systems work, what clinical features define a safe and effective device, and how endocrine surgeons and otolaryngologists can evaluate these systems for integration into practice.
By the end, you’ll understand the core components of a thyroid RFA system, the safety features that matter most during ablation, and how patient selection criteria influence outcomes.
A thyroid RFA system is a medical device platform that delivers radiofrequency energy to heat and ablate targeted thyroid tissue. The system consists of two primary components: a generator that produces the electrical current and an electrode that delivers that energy directly into the nodule under ultrasound guidance.
During the procedure, the electrode tip generates localized heat, causing coagulative necrosis in the nodule. Over the following months, the ablated tissue gradually shrinks as the body reabsorbs it. Clinical studies report average volume reductions between 50% and 80% at 12 months for solid benign nodules.
Unlike thyroid removal, RFA preserves the surrounding thyroid parenchyma. Patients typically maintain normal thyroid function and avoid the need for lifelong hormone replacement therapy.
The clinician inserts a thin needle electrode through the skin into the thyroid nodule using real-time ultrasound imaging. High-frequency alternating current flows from the generator through the electrode, creating frictional heat at the tip. This thermal energy destroys nodule cells while sparing healthy tissue beyond the ablation zone.
Most practitioners use the “moving shot” technique, repositioning the electrode from the deepest portion of the nodule toward the surface in overlapping passes. This approach distributes thermal energy evenly and reduces the risk of undertreating any single region.
Hydrodissection, injecting fluid between the nodule and critical structures like the recurrent laryngeal nerve or trachea, creates a protective buffer zone. The procedure typically takes less than one hour and allows same-day discharge under local anesthesia.
The generator is the control center of any RFA system. When assessing generators for thyroid nodule ablation, clinicians should prioritize the following capabilities.
Tissue impedance changes as ablation progresses. A generator that continuously monitors impedance helps clinicians identify when target tissue has been adequately treated and prevents over-ablation. This feedback loop supports consistent, reproducible results across different nodule types and sizes.
Precise temperature regulation at the electrode tip allows clinicians to maintain therapeutic ranges while avoiding excessive heat that could damage nearby structures. Temperature-controlled modes automatically adjust power output based on real-time readings, adding a layer of safety during treatment.
Flexible generators offer several modes for different clinical scenarios. Continuance mode delivers constant RF output with automatic impedance-based adjustments, while temperature mode maintains a user-defined thermal target. This versatility enables tailored treatment protocols based on nodule characteristics and clinician preference.
The VIVA combo RF System from STARMED America incorporates all four operating modes along with audible alerts and automatic shutoff to enhance procedural safety.
Electrode design directly impacts how precisely and safely clinicians can treat nodules in the confined anatomical space of the thyroid.
Internally cooled electrodes circulate fluid through the shaft, dissipating heat away from the insertion point. This design prevents tissue charring near the skin surface and allows controlled energy delivery deeper in the nodule. Internal cooling helps maintain predictable ablation zones without excessive collateral thermal injury.
Thyroid nodules vary widely in size and shape. Electrodes with adjustable active tip lengths let clinicians match ablation zone dimensions to nodule anatomy in real time. Treating a small 1 cm nodule requires a different active tip than addressing a 4 cm nodule, and a single adjustable electrode eliminates the need to stock multiple devices.
STARMED America’s VIVA II RF Electrode offers five active tip sizes in one device, enabling tailored treatment without changing instruments mid-procedure.
A sharp, thin electrode shaft reduces tissue trauma during insertion and allows precise positioning under ultrasound guidance. Shorter shafts designed specifically for thyroid anatomy improve maneuverability in the neck’s limited working space.
FDA clearance confirms that a device has met safety and effectiveness standards through rigorous review. For thyroid RFA, this distinction matters because it supports institutional value analysis committee approval, payer recognition, and clinician confidence.
STARMED America holds the first FDA indication for RFA of thyroid nodules in the United States. This regulatory milestone, combined with more than 300 peer-reviewed publications validating the technology, gives clinicians evidence-based assurance when integrating the platform into practice.
As of January 1, 2025, CMS established dedicated CPT codes 60660 and 60661 for percutaneous radiofrequency ablation of thyroid nodules. These codes formalize reimbursement pathways and remove a historical barrier to adoption.
Appropriate patient selection is fundamental to achieving favorable outcomes with thyroid RFA. Clinical guidelines recommend confirming benign status with two separate fine-needle aspiration biopsies, or one biopsy combined with definitively benign ultrasound features.
Ideal candidates typically present with:
Predominantly cystic nodules respond less predictably to RFA; ethanol ablation may be more appropriate for those cases. Nodules located immediately adjacent to the vocal cord nerve, esophagus, or major vessels require careful assessment and may not be suitable for thermal ablation.
For clinicians weighing thyroid ablation vs surgery, the decision hinges on matching treatment modality to patient characteristics and clinical goals.
Multi-center data demonstrate volume reduction rates between 50% and 90% at 12 months following RFA. Complication rates remain low, with major complications occurring in fewer than 2% of cases in large studies. Temporary voice changes affect approximately 1.4% of patients, with permanent injury occurring in roughly 0.1%.
Thyroid removal remains the gold standard for confirmed malignancy, nodules requiring definitive pathology, and cases unsuitable for ablation. For benign nodules in appropriate candidates, RFA offers faster recovery, no visible scar, thyroid preservation, and avoidance of lifelong hormone supplementation.
According to a 2025 AAO–HNS Bulletin article, quality of life metrics improved significantly following RFA for both benign nodules and select papillary thyroid microcarcinomas, with patients reporting better psychological and social outcomes.
Mastering thyroid RFA requires hands-on experience beyond didactic learning. Clinicians new to the procedure benefit from structured training pathways that include phantom simulation, live case observation, and real-time proctoring during initial procedures.
STARMED America’s U.S. Thyroid RFA Training Program, led by practicing thyroid specialists, guides physicians from foundational skills through independent practice. This support extends to reimbursement navigation, clinical case consultation, and patient education resources that help practices build sustainable RFA programs.
The VIVA combo RF System integrates with standard imaging modalities including ultrasound, CT, and fluoroscopy. This compatibility minimizes retraining for staff already proficient in image-guided procedures and allows practices to incorporate RFA without overhauling existing infrastructure.
Because thyroid RFA is an outpatient procedure performed under local anesthesia with same-day discharge, practices can schedule cases efficiently without requiring operating room time or inpatient beds. This workflow flexibility supports higher patient throughput while reducing overhead costs compared to traditional thyroid operations.
Selecting the right thyroid RFA system means assessing generator capabilities, electrode design, regulatory status, and available clinical support. Prioritize systems with real-time impedance and temperature monitoring, internally cooled electrodes with adjustable active tips, and FDA-cleared indications backed by published evidence.
Patient outcomes depend on both device performance and clinician expertise. Partnering with a manufacturer that offers structured training, reimbursement assistance, and ongoing clinical support positions your practice to deliver safe, effective, and patient-centered care.
To explore how STARMED America’s thyroid RFA technology can fit your clinical goals, visit the thyroid RFA page or contact the clinical team directly.
A thyroid RFA system consists of a radiofrequency generator and a needle electrode. The generator produces controlled electrical current, while the electrode delivers thermal energy into the nodule under ultrasound guidance to cause tissue shrinkage.
STARMED America pioneered the first thyroid-dedicated electrode and holds the first FDA indication for thyroid nodule RFA in the United States. The VIVA combo RF System features Continuance Mode with real-time impedance feedback and internally cooled electrodes for precise, safe ablations.
Clinical studies consistently report 50% to 80% average volume reduction at 12 months for benign solid nodules. Individual results vary based on nodule characteristics, treatment technique, and patient factors.
As of January 2025, CMS established CPT codes 60660 and 60661 specifically for percutaneous thyroid RFA. Coverage varies by payer and plan; practices should verify pre-authorization before scheduling procedures.
Clinicians use the trans-isthmic approach to avoid the tracheoesophageal groove where the nerve travels. Hydrodissection creates a protective fluid layer, and real-time voice monitoring during the procedure allows immediate detection of any nerve irritation.
Most patients return to normal daily activities within 24 to 48 hours. Mild neck soreness or bruising at the needle site typically resolves with over-the-counter pain relief. There is no visible scar and no hospital stay required.
Thyroid removal remains the standard of care for most thyroid cancers. However, select low-risk papillary thyroid microcarcinomas (under 1 cm) may be appropriate for RFA in patients who are not candidates for or decline surgical intervention. STARMED America’s clinical team can help assess case-by-case candidacy.
Do you have more questions to ask about ablation? Our team is happy to help. Contact us to learn more about implementing RFA in your practice.
See how safe and effective STARMED’s industry-leading equipment is in practice.
By submitting this form, you consent to receive marketing emails from STARMED America at the email provided. You can unsubscribe at any time. Please see our privacy policy for more information.
